主要文件

查看所有文档

M1000000

甲氨蝶呤

Name: 甲氨蝶呤
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

(+)-氨甲蝶呤, 4-氨基-N¹⁰-甲基巯基-L-谷氨酸, MTX, 氟安定, 氨甲叶酸, 氨甲喋呤

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₀H₂₂N₈O₅

化学文摘社编号:

59-05-2

分子量:

454.44

UNSPSC Code:

41116107

NACRES:

NA.24

PubChem Substance ID:

329817845

MDL number:

MFCD00064370

Beilstein/REAXYS Number:

70669

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

methotrexate

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CN(Cc1cnc2nc(N)nc(N)c2n1)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O

InChI

1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1

InChI key

FBOZXECLQNJBKD-ZDUSSCGKSA-N

Gene Information

human ... DHFR(1719)

说明

General description

本品按现行药典规定交付。所有为支持本产品而提供的信息，包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持，请访问现行药典网站。

Application

甲氨蝶呤EP 参考标准品设计用于欧洲药典规定的实验室测试。

Packaging

本品按照现行药典要求提供。有关当前单位数量，请见EDQM 参考目录。

Other Notes

可能适用相应的销售限制。

Still not finding the right product?

Explore all of our products under 甲氨蝶呤

pictograms

GHS06,GHS08

signalword

Danger

hcodes

H301,H341,H360D,H372

pcodes

P202 - P260 - P264 - P280 - P301 + P310 - P405

Hazard Classifications

Acute Tox. 3 Oral - Muta. 2 - Repr. 1B - STOT RE 1

target_organs

Liver,Bone marrow

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial.

Joshua F Baker et al.

Annals of the rheumatic diseases, 73(11), 1968-1974 (2013-08-02)

To determine if early MRI measures predict X-ray progression at 1 and 2 years in a large RA trial cohort. This study included 256 methotrexate (MTX)-naïve RA patients from a randomised placebo-controlled trial of golimumab (GO-BEFORE). MRIs of wrist and 2nd-5th

Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy.

Kalle Jyri Aaltonen et al.

The Journal of rheumatology, 42(3), 372-378 (2015-01-17)

Because of the role of tumor necrosis factor (TNF) in host defense, it was hypothesized that its inhibition might lead to an increased risk of malignancies and infections. The objective of our study was to assess the incidence of serious

Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial.

Axel Finckh et al.

Arthritis research & therapy, 16(5), 458-458 (2014-10-16)

Calcium pyrophosphate deposition (CPPD) may cause severe arthropathy, major joint destruction and treatment options are limited. The aim of this study was to test the therapeutic efficacy of methotrexate (MTX) in chronic or recurrent CPPD arthropathy. Patients with CPPD arthropathy

查看所有相关文献

全球贸易项目编号

货号	GTIN
M1000000	04061834037637